abo1009-dp
VaccineexperimentalCOVID-19
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 8, 2022 (NCT05434585)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05433194 | Phase 1 | Aug 22, 2022 | Abogen Biosciences Co. Ltd. |
| NCT05434585 | Phase 1 | Jul 8, 2022 | Abogen Biosciences Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abogen Biosciences Co. Ltd. | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1